Anticoagulant properties of the vascular endothelium

Thrombosis and Haemostasis

Volumn 77, Issue 3, 1997, Pages 408-423

  Bombeli, Thomas ^a,b   Mueller, Michele ^a   Haeberli, André ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; DERMATAN SULFATE; HEPARIN COFACTOR II; LIPOCORTIN 5; PROTEASE NEXIN I; PROTEIN C; PROTEIN S; PROTEOHEPARAN SULFATE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; AORTA; BINDING SITE; CELL SURFACE; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SYNTHESIS; REVIEW; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

EID: 0030950165     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655981     Document Type: Review

References (304)

1. Beresford CH, Owen MC. Antithrombin III. Int J Biochem 1990; 22: 121-8.
2. Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-7.
3. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
4. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-67.
5. Hatton MWC, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-70.
6. Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-7.
7. Marcum JA, Fritze L, Galli SJ, Karp G, Rosenberg RD. Microvascular heparin-like species with anticoagulant activity. Am J Physiol 1983; 245: H725-H33.
8. Colburn P, Buonassisi V. Anticlotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochem Biophys Res Commun 1982; 104: 220-7.
9. Marcum JA, Rosenberg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126: 365-72.
10. Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261: 7507-17.
11. Nader HB, Dietrich CP, Buonassisi V, Colburn P. Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci USA 1987; 84: 3565-9.
12. Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg RD. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992; 267: 4859-69.
13. Kojima T, Shworak N, Rosenberg RD. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem 1992; 267: 4870-7.
14. Lindblom AI, Carlstedt I, Fransson LA. Identification of the core proteins in proteoglycans synthesized by vascular endothelial cells. Biochem J 1989; 261: 145-52.
15. Mertens G, Cassiman JJ, van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992; 267: 20435-43.
16. Shworak NW, Shirakawa M, Colliec-Jouault S, Liu J, Mulligen RC, Birinyi LK, Rosenberg RD. Pathway specific regulation of the synthesis of anticoagulantly active heparan sulfate. J Biol Chem 1994; 269: 24941-9.
17. Justus AC, Hoggatt AM, Faulk WP. Heparan-dependent endothelial antithrombin binding is increased by butyrate. Thromb Res 1995; 80: 125-33.
18. Bauer PI, Machovich R, Aranyi R, Büki G, Csonka E, Horvath I. Mechanism of thrombin binding to endothelial cells. Blood 1983; 61: 368-72.
19. Shimada K, Ozawa T. Evidence that cell surface heparan sulfate is involved in the high affinity thrombin binding to cultured porcine aortic endothelial cells. J Clin Invest 1985; 75: 1308-16.
20. Hatton MWC, Moar SL. A role for pericellular proteoglycan in the binding of thrombin or antithrombin III by the blood vessel endothelium? The effects of proteoglycan-degrading enzymes and glycosaminoglycan-binding proteins on 125-I-thrombin binding by the rabbit aorta in vitro. Thromb Haemost 1985; 53: 228-34.
21. Bartha K, Kovacs T, Lerant I, Papp B, Csonka E, Kolev K, Machovich R. Interaction of antithrombin III and thrombin-antithrombin III complex with cultured aortic endothelial cells. Thromb Res 1987; 47: 541-52
22. Stern D, Nawroth P, Marcum JA, Handley D, Kisiel W, Rosenberg RD, Stern K. Interaction of antithrombin III with bovine aortic segments: role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 1985; 75: 272-9.
23. Lollar P, MacIntosh SC, Owen WG. Reaction of antithrombin III with thrombin bound to the vascular endothelium: analysis in a recirculating perfused rabbit heart preparation. J Biol Chem 1984; 259: 4335-8.
24. Nydahl S, Frebelius S, Swedenborg. Thrombin inactivation and the effects of antithrombin and heparin in a recirculating Langendorff preparation. Thromb Res 1992; 65: 365-76.
25. Delvos U, Meusel P, Preissner KT, Müller-Berghaus G. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells - a comparative study of two anticoagulant mechanism. Thromb Haemost 1987; 57: 87-95.
26. Shimada K, Kobayashi M, Kimura S, Nishinaga M, Takeuchi K, Ozawa T. Anticoagulant heparin-like glycosaminoglycans on endothelial cell surface. Jpn Circ J 1991; 55: 1016-21.
27. Lowe-Krentz LJ, Joyce JG. Venous and aortic porcine endothelial cells cultured under standardized conditions synthesize heparan sulfate chains which differ in charge. Anal Biochem 1991; 193: 155-63.
28. Justus AC, Roussev R, Norcross JL, Faulk WP. Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb Res 1995; 79: 175-86.
29. Marcum JA, McKenney JB, Rosenberg RD. The acceleration of thrombin-antithrombin complex formation in rat hindquarters via naturally occurring heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-50.
30. Xu Y, Slayter HS. Immunocytochemical localization of endogenous antithrombin III in the vasculature of rat tissues reveals location of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem 1994; 42: 1365-72.
31. Felsch JS, Owen WG. Endogenous antithrombin associated with microvasculature endothelium. Quantitative analysis in perfused rat hearts. Biochemistry 1994; 33: 818-22.
32. Cooper ST, Neese LL, Di Cuccio MN, Liles DK, Hoffman M, Church FC. Vascular localization of the heparin-binding serpins antithrombin, heparin cofactor II, and protein C inhibitor. Thromb Haemost 1996; 2: 185-91.
33. De Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-304.
34. 125I-antithrombin III binds to proteoheparin sulphate at the subendothelium of the rabbit aorta in vitro. Blood Vessels 1988; 25: 12-8.
35. Hatton MWC, Moar SL, Richardson M. On the interaction of rabbit antithrombin III with the luminal surface of the normal and deendothelialized rabbit thoracic aorta in vitro. Blood 1986; 67: 878-86.
36. Frebelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall - role of antithrombin and heparin. Thromb Haemost 1994; 71: 147-53.
37. Busch C, Owen WG. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 1982; 69: 726-34.
38. Preissner KT, Müller-Berghaus G. Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvment of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987; 262: 12247-51.
39. Williams EC, Huppert BJ, Asakura S. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins. J Lab Clin Med 1992; 120: 159-66.
40. Preissner KT, De Boer H, Pannekoek H, De Groot PG. Thrombin regulation by physiological inhibitors: the role of vitronectin. Semin Thromb Haemost 1996, 22: 165-72.
41. Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry 1988; 27: 752-9.
42. Struss DJ. Storck RE, Zimmermann P. The inhibition of thrombin and chymotrypsin by heparin cofactor II. Thromb Res 1992; 68: 45-56.
43. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
44. Sié P, Dupouy D, Caranobe C, Petitou M, Boneu B. Antithrombotic properties of a dermatan sulfate hexasaccharide fractionated by affinity for heparin cofactor II. Blood 1993; 81: 1771-7.
45. Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high-affinity. J Biol Chem 1990; 265: 18263-71.
46. Faber V, Quentin-Hoffmann E, Breuer B, Schittny J, Voler W, Kresse H. Colocalization of a large heterodimeric proteoglycan with basement membrane proteins in cultured cells. Eur J Cell Biol 1992; 59: 37-43.
47. Schmidt G, Hausser H, Kresse H. Interaction of the small proteoglycan decorin with fibronectin. Involvement of the sequence NKISK of the core protein. Biochem J 1991; 280: 411-6.
48. Vogel KG, Peterson DW. Extracellular, surface and intracellular proteoglycans produced by human embryo lung fibroblasts in culture (IMR-90). J Biol Chem 1981; 256: 13235-40.
49. Järveläinen HT, Kinsella MG, Wight TN, Sandell LJ. Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 1991; 266: 23274-9.
50. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-102.
51. Schittny JC, Kresse H, Burri PH. Immunostaining of a heterodimeric dermatan sulphate proteoglycan is correlated with smooth muscles and some basement membranes. Histochem Cell Biol 1995; 103: 271-9.
52. Kinsella MG, Wight TN. Formation of high molecular weight dermatan sulfate proteoglycan in bovine aortic endothelial cell cultures. Evidence for transglutaminase-catalyzed cross-linking to fibronectin. J Biol Chem 1990; 265: 17891-8.
53. Kresse H, Hausser H, Schonherr E, Bittner K. Biosynthesis and interactions of small chondroitin/dermatan sulfate proteoglycans. Eur J Clin Chem Clin Biochem 1994; 32: 259-66.
54. Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-13.
55. Cavari S, Vannucchi S. Glycosaminoglycans exposed on the endothelial cell surface. Binding of heparin-like molecules derived from serum. FEBS Lett 1993; 323: 155-61.
56. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262: 169-75.
57. Kaji T, Itoh F, Hayakawa Y, Oguma Y, Sakuragawa N. Interaction of thrombin with heparin cofactor II and antithrombin III on prostacyclin production by cultured endothelial cells. Thromb Res 1989; 56: 99-108.
58. Kaji T, Ejiri N, Hayakawa Y, Hayasi T, Sakuragawa N: Heparin cofactor II inhibits thrombin stimulated release of tissue plasminogen activator from cultured human endothelial cells in the presence of dermatan sulfate. Thromb Res 1990; 59: 269-77.
59. Whinna HC, Choi HU, Rosenberg LC, Church FC. Interaction of heparin cofactor II with biglycan and decorin. J Biol Chem 1993; 268: 3920-6.
60. Shirk RA, Church FC, Wagner WD. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler Thromb Vasc Biol 1996; 16: 1138-46.
61. Arisaka T, Mitsumata M, Kawasumi M, Tohjima T, Hirose S, Yoshida Y. Effects of shear stress on glycosaminoglycan synthesis in vascular endothelial cells. Ann NY Acad Sci 1995; 748: 543-53.
62. Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-82.
63. Tollefsen DM, Pestka CA. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. J Clin Invest 1985; 75: 496-502.
64. Cella G, Boeri G, Saggiorato G, Paolini R, Luzzatto G, Terribile VI. Interaction between histidine-rich glycoprotein and platelet factor 4 with dermatan sulfate and low-molecular-weight dermatan sulfate. Angiology 1992; 43: 59-65.
65. Zammit A, Dawes J. Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate. Blood 1995; 85: 720-9.
66. Rezaie AR, Esmon CT. Tryptophans 231 and 234 in protien C report the Ca(2+)-dependent conformational change required for activation by the thrombin-thrombomodulin complex. Biochemistry 1995; 34: 12221-6.
67. Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 1985; 260: 2007-13.
68. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-92.
69. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984; 259: 13986-93
70. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-41.
71. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-22.
72. Stern DM, Nawroth PP, Harris K, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C-protein S-mediated inactivation of factor Va. J Biol Chem 1986; 261: 713-20.
73. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-9.
74. Tsiang M, Lentz S, Sadler JE. Functional domains of membrane bound thrombomodulin: EGF-like domains four to six and the serine/threonine rich domain are required for cofactor activity. J Biol Chem 1992; 267: 6164-72.
75. Parkinson JF, Nagashima M, Kuhn I, Jeonard J, Morser J. Structure-function studies of the epidermal growth factor domains of human thrombomodulin. Biochem Biophys Res Commun 1992; 185: 567-74.
76. Gerlitz B, Hassell T, Vlahos CJ, Parkinson JF, Bang NU, Grinnell BW. Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine 474. Biochem J 1993; 195: 131-7.
77. Bourin MC, Lundgren-Akerlund E, Lindahl U. Isolation and characterization of the glycosaminoglycan component of rabbit thrombomodulin proteoglycan. J Biol Chem 1990; 265: 15424-31.
78. Maruyama I, Bell CE, Majerus PW. Thrombomodulin found on endothelium of arteries, veins, capillaries, and lymphatics and on syncytiothrophoblast of human placenta. J Cell Biol 1985; 101: 363-72.
79. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem 1988; 104: 628-34.
80. Ogura M, Ito T, Maruyama I, Takamatsu J, Yamamoto S, Ogawa K, Nagura H, Saito H. Localization and biosynthesis of functional thrombomodulin in human megakaryocytes and a human megakaryoblastic cell line (MEG-01). Thromb Haemost 1990; 64: 297-303.
81. McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 1991; 78: 3128-36.
82. Conway EM, Nowakowski B, Steiner-Mosonyi M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood 1992; 80: 1254-63.
83. Soff GA, Jackman RW, Rosenberg RD. Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood 1991; 77: 515-24.
84. De Bault LE, Esmon NL, Olson JR, Esmon CT. Distribution of the thrombomodulin antigen in the rabbit vasculature. Lab Invest 1986; 54: 179-86.
85. Wong V, Hofman F, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res 1991; 556: 1-9.
86. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin catalyzed fibrin formation and factor V activation. J Biol Chem 1983; 258: 12238-44.
87. Polgar J, Lerant I, Muszbek L, Machovich R. Thrombomodulin inhibits the activation of factor XIII by thrombin. Thromb Res 1986; 43: 585-95.
88. Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12268-73.
89. Parkinson JF, Bang NU, Garcia JGN. Recombinant human thrombomodulin attenuates the inflammatory response of thrombin-stimulated human endothelial cells. Thromb Haemost 1991; 65: 825-32.
90. Bourin MC, Lindahl U. Functional role of the polysaccharide component of rabbit thrombomodulin proteoglycan: effects on inactivation of thrombin by antithrombin, cleavage of fibrinogen by thrombin and thrombin-catalyzed activation of factor V. Biochem J 1990; 270: 419-25.
91. Parkinson JF, Vlahos CJ, Yan SCB, Bang N. Recombinant human thrombomodulin: regulation of cofactor activity and anticoagulant function by chondroitin sulphate. Thromb Haemost 1991; 65: 874-83.
92. Koyama T, Parkinson J, Sié P, Bang N, Müller-Berghaus G, Preissner KT. Different glycoforms of human thrombomodulin: their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. Eur J Biochem 1991; 198: 563-71.
93. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-42.
94. Ye J, Esmon NL, Esmon CT, Johnson A. The active site of thrombin is altered upon binding to thrombomodulin: two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem 1991; 266: 23016-22.
95. 2+ for rapid activation by the thrombin-thrombomodulin complex. J Biol Chem 1994; 269: 3151-57.
96. Parkinson J, Garcia J, Bang N. Decreased thrombin affinity of cell surface thrombomodulin following treatment of cultured endothelial cells with γ-D-xyloside. Biochem Biophys Res Commun 1990; 169: 177-84.
97. Thompson EA, Salem HH, Factors IXa, Xa, XIa and activated protein C do not have protein C activating ability in the presence of thrombomodulin. Thromb Haemost 1988; 59: 339-47.
98. Freyssinet JM, Wiesel ML, Grunebaum L, Pereillo JM, Gauchy J, Schuhler S, Freund G, Cazenave JP. Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids: enhancement by sulphated polysaccharides. Biochem J 1989; 261: 341-8.
99. Nishioka J, Ido M, Hayashi T, Suzuki K. The Gla(26) residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va. Thromb Haemost 1996; 75: 275-82.
100. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-6.
101. Hirokawa K, Aoki N. Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J Biochem Tokyo 1990; 108: 839-46.
102. Horie S, Kizaki K, Ishii H, Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells. Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP. Biochm J 1992; 281: 149-54.
103. Hirokawa K, Aoki N. Up-regulation of thrombomodulin by activation of histamine H1-receptors in human umbilical vein endothelial cells in vitro. Biochem J 1991; 276: 739-46.
104. Kapiotis S, Besemer J, Bevec D, Valent P, Bettelheim P, Lechner K, Speiser W. Interleukin-4 counteracts pyrogen-induced down-regulation of thrombomodulin in cultured human vascular endothelial cells. Blood 1991; 78: 410-8.
105. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-9.
106. Conway EM, Liu L, Nowakowski B, Steiner-Mosonyi M, Jackman RW. Heat shock of vascular endothelial cells induces an up-regulatory transcriptional response of the thrombomodulin gene that is delayed in onset and does not attenuate. J Biol Chem 1994; 269: 22804-10.
107. Takada Y, Shinkai F, Kondo S, Yamamoto S, Tsuboi H, Korenaga R, Ando J. Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem Biophys Res Commun 1994; 205: 1345-53.
108. Malek AM, Jackman R, Rosenberg RD, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 1994; 74: 852-61.
109. Bartha K, Brisson C, Archipoff G, de-la Salle C, Lanza F, Cazenave JP, Beretz A. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem 1993; 268: 421-8.
110. Horie S, Ishii H, Hara H, Kazama M. Enhancement of thrombin-thrombomodulin-catalysed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem J 1994; 301: 683-92.
111. Slungaard A, Key NS. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 1994; 269: 25549-55.
112. Bourin MC, Boffa MC, Bjork I, Lindahl U. Functional domains of rabbit thrombomodulin. Proc Natl Acad Sci USA 1986; 83: 5924-32.
113. Archipoff G, Beretz A, Freyssinet J, Klein-Soyer C, Brisson C, Cazenave J. Heterogenous regulation of constitutive thrombomodulin of inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem J 1991; 273: 679-86.
114. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1989; 83: 3460-9.
115. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-32.
116. Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL, Esmon CT, Jacob HS. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci USA 1990; 87: 7095-103.
117. Ogawa S, Gerlach H, Esposito C, Pasagian-Macaulay A, Brett J, Stern D. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium: increased monolayer permeability and induction of procoagulant properties. J Clin Invest 1990; 85: 1090-9.
118. Lentz SR, Sadler JE. Inhibtion of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-12.
119. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90: 2565-74.
120. Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J Lab Clin Med 1994; 123: 874-83.
121. Ohij T, Urano H, Shirahata A, Yamagishi M, Higashi K, Gotoh S, Karasaki Y. Transforming growth factor beta 1 and beta 2 induce down-modulation of thrombomodulin in human umbilical vein endothelial cells. Thromb Haemost 1995; 73: 812-9.
122. Mukai HY, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br J Haematol 1995; 90: 892-9.
123. Brighton TA, Chesterman CN. Antiphospholipid antibodies and thrombosis. Baillieres Clin Haematol 1994; 7: 541-53.
124. Laszik Z, Carson CW, Nadasdy T, Johnson LD, Lerner MR, Brackett DJ, Esmon CT, Silva FG. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Lab Invest 1994; 70: 862-71.
125. Drake TA, Cheng J, Chang A, Taylor FB. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E. coli sepsis. Am J Pathol 1993; 142: 1458-65.
126. Schwalbe RA, Ryan J, Stern DM, Kisiel W, Dahlbäck B, Nelsestuen GL. Protein structural requirements and properties of membrane binding by γ-carboxyglutamic acid-containing plasma proteins and peptides. J Biol Chem 1989; 264: 20288-95.
127. Sugo T, Dahlbäck B, Holmgren A, Stenflo J. Calcium binding of bovine protein S. Effect of thrombin cleavage and removal of the γ-carboxyglutamic acid-containing region. J Biol Chem 1986; 261: 5116-22.
128. Dahlbäck B, Hildebrand B, Malm J. Characterization of functionally important domains in vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265: 8127-33.
129. Dahlbäck B, Hildebrand B, Linse S. Novel type of very high-affinity calcium-binding sites in β-hydroxy-asparagine-containing epidermal growth factor-like domains in vitamin K-dependent protein S. J Biol Chem 1990; 265: 18481-9.
130. Nelson RM, Long GL. Binding of protein S to C4b-binding protein: mutagenesis of protein S. J Biol Chem 1992; 267: 8140-8.
131. Hardig Y, Dahlbäck B. The amino-terminal module of the C4b-binding protein beta-chain contains the protein S binding site. J Biol Chem 1996; 271: 20861-7.
132. Hillarp A. Molecular analysis of the beta-chain of human C4b-binding protein. Scand J Clin Lab Invest Suppl 1991; 204: 57-64.
133. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiences of protein S: protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. J Clin Invest 1988; 81: 1445-53.
134. Stern DM, Nawroth PP, Harris K, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C-protein S-mediated inactivation of factor Va. J Biol Chem 1986; 261: 713-9.
135. Hackeng TM, Hessing M, van't Veer C, Meijer-Huizinga F, Meijers JC, de-Groot PG, van Mourik JA, Bouma BN. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993; 268: 3993-4000.
136. Lu DS, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
137. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-43.
138. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V-R506Q mutation. Thromb Haemost 1996; 76: 208-14.
139. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem 1982; 257: 1443-9.
140. Jane SM, Hau L, Salem HH. Regulation of activated protein C by factor Xa. Blood Coag Fibrinolysis 1991; 2: 723-31.
141. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 1988; 263: 14884-9.
142. Hackeng TM, van't Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
143. Heeb MJ, Masters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2827-34.
144. Heeb MJ, Rosing J, Bakker H, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-34.
145. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
146. Koppelman SJ, van't Veer C, Sixma JJ, Bouma BN. Synergistic inhibition of the intrinsic factor X activation by protein S and C4b-binding protein. Blood 1995; 86: 2653-62.
147. van Wijnen M, Stam JG, van't Veer C, Meijers JCM, Reitsma PH, Bertina RM, Bouma BN. The interaction of protein S with the phospholipid surface is essential for the activated protein C independent activity of protein S. Thromb Haemost 1996; 76: 397-403.
148. van't Veer C, Hackeng TM, Biesbroeck D, Sixma JJ, Bouma BN. Increased thrombin formation in protein S deficient plasma under flow conditions on endothelial cell matrix: an independent anticoagulant function of protein S in plasma. Blood 1995; 85: 815-23.
149. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-8.
150. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-9.
151. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
152. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-83.
153. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
154. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-23.
155. Higuchi D, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-9.
156. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner V. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-8.
157. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-11.
158. Hamamoto, T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor. Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 1993; 268: 8704-11.
159. Lindhout T, Franssen J, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-7.
160. van't Veer C, Hackeng TM, Delahaye C, Sixma JJ, Bouma BN. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994; 84: 1132-9.
161. Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990; 87: 7623-9.
162. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-71.
163. Welsch D, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res 1991; 64: 213-21.
164. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner V, Nordfang Q. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6: 388-95.
165. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-9.
166. Almus FE, Rao LV, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-11.
167. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991; 2: 713-22.
168. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995; 34: 5725-32.
169. Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1996; 7: 470-6.
170. Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res 1994; 75: 609-19.
171. Hamamoto T, Kisiel W. Full-length tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Thromb Res 1995; 80: 291-302.
172. Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, Saito H. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 1996; 271: 5914-20.
173. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773-82.
174. Valentin S, Reutelingsperger CPM, Nordfang O, Lindhout T. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa. Thromb Haemost 1995; 74: 1478-85.
175. Valentin S, Schousboe I. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemost 1996; 75: 796-800.
176. Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-74.
177. Kazama Y, Komiyama Y, Kisiel W. Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood 1993; 81: 676-83.
178. Ho GY, Toomey JR, Broze GJ, Schwartz AL. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271: 9497-502.
179. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cell in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2055-61.
180. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-26.
181. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-60.
182. Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, Misugi K, Umeda M, Miyazaki K. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem Tokyo 1994; 116: 939-45.
183. Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994; 84: 4384 (letter).
184. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266-72.
185. Römisch J, Pâques EP. Annexins: calcium-binding proteins of multi-functional importance? Med Microbiol Immunol 1991; 180: 109-19.
186. Funakoshi T, Heimark RL, Hendrickson LE, McMullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry 1987; 26: 5572-9.
187. Reutelingsperger CPM, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 1985; 151: 625-32.
188. Reutelingsperger CPM, Kop JM, Hornstra G, Hemker HC. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Inhibition of the phospholipid dependent factor Xa-catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids. Eur J Biochem 1988; 173: 171-8.
189. Sun J, Salem HH, Bird P. Nucleolus and cytoplasmatic localization of annexin V. FEBS Lett 1992; 314: 425-31.
190. Römisch J, Schüler E, Bastian B, Bürger T, Dunkel FG, Schwinn A, Hartmann AA, Pâques EP. Annexin I-VI. quantitative determination in different human cell types and in plasma after myocardial infarction. Blood Coagulation and Fibrinolysis 1992; 3: 11-9.
191. Flaherty MJ, West S, Heimark R, Fujikawa K, Tait FJ. Placental anticoagulant protein I. Measurement in extracellular fluids and cells of the haemostatic system. J Lab Clin Med 1990; 115: 174-83.
192. Murphy CT, Peers SH, Forder RA, Flower RJ, Carey F, Westwick J. Evidence for the presence and location of annexins in human platelets. Biochem Biophys Res Commun 1992; 189: 1739-45.
193. 2+-dependent membrane-binding proteins in normal erythrocytes and erythrocytes from patients with chronic myelogenous leukemia. Blood 1990; 75: 1337-44.
194. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-51.
195. Meers P, Mealy T. Calcium-dependent annexin V binding to phospholipids: stoichiometry, specificity, and role of negative charge. Biochemistry 1993; 32: 11711-8.
196. Concha NO, Head JF, Kaetzel MA, Dedman JR, Seaton BA. Annexin V forms calcium-dependent trimeric units on phospholipid vesicles. FEBS Lett 1992; 314: 159-64.
197. Andree HAM, Stuart MCA, Hermens WTH, Reutelingsperger CPM, Hemker HC, Frederik PM, Willems GM. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-13.
198. Thiagarajam P, Tait JF. Binding of Annexin V/Placental anticoagulant protein I to platelets. J Biol Chem 1990; 265: 17420-5.
199. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123: 741-50.
200. Thiagarajam P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991; 266: 24302-9.
201. van Heerde WL, Poort S, van't Veer C, Reutelingsperger CPM, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J 1994; 302: 305-11.
202. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic endothelial cells become procoagulant. Blood, in press.
203. Gramzinski RA, Broze GJ Jr, Carson SD. Human fibroblast tissue factor is inhibited by lipoprotein-associated coagulation inhibitor and placental anticoagulant protein but not by apolipoprotein A-II. Blood 1989; 73: 983-90.
204. Ravanat C, Archipoff G, Beretz A, Freund G, Cazenave JP, Freyssinet JM. Use of annexin V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells. Biochem J 1992; 282: 7-13.
205. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsperger CP, de Groot PG. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler Thromb 1994; 14: 824-32.
206. Sun J, Bird P, Salem HH. Effects of annexin V on the activity of the anticoagulant proteins C and S. Thromb Res 1993; 69: 279-88.
207. van Ryn-McKenna J, Merk H, Muller TH, Buchanan MR, Eisert WG. The effects of heparin and annexin V on fibrin accretion after injury in the jugular veins of rabbits. Thromb Haemost 1993; 69: 227-34.
208. Römisch J, Seiffge D, Reiner G, Pâques EP, Heimburger N. In-vivo antithrombotic potency of placenta protein 4 (annexin V). Thromb Res 1991; 61: 93-102.
209. van Nostrand WE, McKay LD, Baker JB, Cunningham DD. Functional and structural similarities between protease nexin-1 and C1-inhibitor. J Biol Chem 1988; 263: 3979-86.
210. Sommer J, Gloor SM, Rovelli GF, Hofsteenge J, Nick H, Meier R, Monard D. cDNA sequence coding for a rat glia-derived nexin and its homology to members of the serpin superfamily. Biochemistry 1987; 26: 6407-13.
211. Eaton DL, Baker JB. Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmatic serine-protease-binding factor. J Cell Physiol 1983; 117: 175-83.
212. Laug WE, Aebersold R, Jong A, Rideout W, Bergman BL, Baker JB. Isolation of multiple types of plasminogen activator inhibitor from vascular smooth muscle cells. Thromb Haemost 1989; 61: 517-24.
213. Festoff BW, Rao JS, Hantai D. Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses. J Cell Physiol 1991; 147: 76-84.
214. Gronke RS, Curry TK, Baker JB. Formation of protease nexin-thrombin complexes on the platelet surface. J Cell Biochem 1986; 32: 201-9.
215. Choi B, Suzuki M, Taiseung K, Wagner S, Cunningham DD. Protease nexin-1. Localization in the human brain suggests a protective role against extravasated serine proteases. Am J Path 1990; 137: 741-9.
216. Knauer DJ, Cunningham DD. Protease nexins: cell-secreted proteins which regulate extracellular serine proteases. Trends Biochem Sci 1984; 9: 231-9.
217. Hermans JM, Stone SR. Interaction of activated protein C with serpins. Biochem J 1993; 295: 239-45.
218. Evans DL, McGrogan M, Scott RW, Carrell RW. Protease specificity and heparin binding and activation of recombinant protease nexin-1. J Biol Chem 1991; 266: 22307-12.
219. Wallace A, Rovelli G, Hofsteenge J, Stone SR. Effect of heparin on the glia-derived-nexin thrombin interaction. Biochem J 1989; 257: 191-9.
220. Rovelli G, Stone SR, Guidolin A, Sommer J, Monard D. Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1. Biochemistry 1992; 31: 3542-9.
221. Farrell DH, Cunnigham DD. Glycosaminoglycans on fibroblasts accelerate thrombin inhibition by protease nexin-I. Biochem J 1987; 245: 543-7.
222. Hiramoto SA, Cunningham DD. Effects of fibroblasts and endothelial cells on inactivation of target proteases by protease nexin-1, heparin cofactor II, and C1-inhibitor. J Cell Biochem 1988; 36:199-206.
223. Farrell DH, Wagner SL, Yuan RH, Cunningham DD. Localization of protease nexin-1 on the fibroblast extracellular matrix. J Cell Physiol 1988; 134: 179-84.
224. Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. J Biol Chem 1993; 268: 3720-7.
225. Isaacs J, Savion N, Gospodarowicz D, Shuman MA. Effect of cell density of thrombin binding to a specific site on bovine vascular endothelial cells. J Cell Biol 1981; 90: 670-7.
226. Leroy-Viard K, Jandrot-Perrus M, Tobelem G, Guillin MC. Covalent binding of human thrombin to a human endothelial cell-associated protein. Exp Cell Res 1989; 181: 1-9.
227. Wagner SL, Lau AL, Cunningham DD. Binding of protease nexin-1 to the fibroblast surface alters its target proteinase specificity. J Biol Chem 1989; 264: 611-9.
228. Donovan FM, Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 target protease specificity by collagen type IV. J Biol Cem 1994; 269: 17199-206.
229. Knauer DJ, Thompson JA, Cunningham DD. Protease nexins: cell-secreted proteins that mediate the binding, internalization, and degradation of regulatory serine proteases. J Cell Physiol 1983; 117: 383-9.
230. Rovelli G, Stone SR, Preissner KT, Monard D. Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin and its thrombin complex. Eur J Biochem 1990; 192: 797-806.
231. Chang AC, Detwiler TC. Reactions of thrombin-serpin complexes with thrombospondin. Arch Biochem Biophys 1992; 299: 100-8.
232. Ponte P, Gonzalez-Dewhitt P, Schilling J, Miller J, Hsu D, Greenburg B, Davis K, Wallace W, Lieberburg I, Fuller F. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 1988; 331: 525-31.
233. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-31.
234. van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin II (amyloid beta protein precursor): a platelet α-granule protein. Science 1990; 248: 745-51.
235. van Nostrand WE, Schmaier AH, Farrow JS, Cines DB, Cunningham DD. Protease nexin II/amyloid beta-precursor in blood is a platelet-specific protein. Biochem Biophys Res Commun 1991; 175: 15-21.
236. van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW, Cunningham DD. Protease nexin II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature 1989; 341: 546-50.
237. van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD.' Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem 1990; 265: 9591-9.
238. Schmaier AH, Dahl LD, Rozemuller AJM, Roos RAC, Wagner SL, Chung R, van Nostrand WE. Protease nexin-2/amyloid beta-protein precursor. A tight binding inhibitor of coagulation factor IXa. J Clin Invest 1993; 92: 2540-8.
239. Schmaier AH, Dahl LD, Hasan AA, Cines DB, Bauer KA, van Nostrand WE. Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. Biochemistry 1995; 34: 1171-8.
240. Johnson-Wood KL, Hendriksson T, Seubert F, Oltersdorf T, Lieberburg I, Schenk DB. Identification of secreted beta-amyloid precursor protein binding site on intact human fibroblasts. Biochem Biophys Res Commun 1994; 200: 1685-90.
241. van Nostrand WE, Schmaier AH, Wagner SL. Potential role of protease nexin-2/amyloid beta protein precursor as a cerebral anticoagulant. Ann N Y Acad Sci 1992; 674: 243-9.
242. Kaplan AP, Silverberg M, Ghebrehiwet B. The intrinsic coagulation/kinin pathway-the classical complement pathway and their interactions. Adv Exp Med Biol 1986; 198B: 11-14.
243. Reddigari SR, Silverberg M, Kaplan AP. Assembly of the human plasma kinin-forming cascade along the surface of vascular endothelial cells. Int Arch Allergy Immunol 1995; 107: 93-5.
244. Reddigari SR, Shibayama Y, Brunnee T, Kaplan AP. Human hageman factor (FXII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
245. Ratnoff OD, Everson B, Embury P, Ziats NP, Anderson JM, Emanuelson MM, Malemund CJ. Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates. Proc Natl Acad Sci USA 1991; 88: 10740-6.
246. Kleniewski J, Donaldson VH. Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor. Proc Natl Acad Sci USA 1993; 90: 198-202.
247. Bombeli T, Müller M, Straub PW, Haeberli A. Cyclosporine induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and in whole blood. J Lab Clin Med 1996; 6: 621-31.
248. Rodgers GM, Greenberg CS, Shuman MA. Characterization of the effects of cultured vascular endothelial cells on the activation of blood coagulation. Blood 1983; 61: 1155-62.
249. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, ten Cate H, Hack CE. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-26.
250. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. Modulation of contact system proteases by glycosaminoglycans - selective enhancement of the inhibition of factor XIa. J Biol Chem 1996; 271: 12913-8.
251. Stern DM, Nawroth PP, Kisiel W, Vehar G, Esmon CT. The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X. J Biol Chem 1985; 260: 6717-22.
252. Varadi K, Elodi S. Formation and functioning of the factor IXa-VIII complex on the surface of endothelial cells. Blood 1987; 69: 442-50.
253. O'Brien DP, Johnson D, Byfield P, Tuddenham EGD. Inactivation of factor VIII by factor IXa. Biochemistry 1992; 31: 2805-10.
254. Lamphear BJ, Fay PJ. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood 1992; 80: 3120-8.
255. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-9.
256. Koppelman SJ, Koedam JA, Wijnen M, Stern DM, Nawroth PP, Sixma JJ. Bouma BN. von Willebrand factor as a regulator of intrinsic factor X activation. J Lab Clin Med 1994; 123: 585-92.
257. Lajmanovich A, Hudry-Clergeon G, Freyssinet JM, Marguerie G. Human factor VIII procoagulant activity and phospholipid interaction. Biochim Biophys Acta. 1981; 678: 132-9.
258. Nesheim M, Pittman DD, Giles AR, Pass DN, Wang JH, Slonosky D, Kaufman RJ. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 1991; 266: 17815-22.
259. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on the activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-34.
260. Biedermann B, Rosenmund A, Müller M, Kohler HP, Haeberli A, Straub PW. Human endothelial cells suppress prothrombin activation in non-anticoagulated whole blood in vitro. J Lab Clin Med 1994; 124: 339-48.
261. Kohler HP, Müller M, Bombeli T, Straub PW, Haeberli A. The suppression of the coagulation of non-anticoagulated whole blood in vitro by human umbilical vein endothelial cells cultivated on microcarriers is not dependent on protein C activation. Thromb Haemost 1995; 73: 719-26.
262. Bombeli T, Müller M. Straub PW, Haeberli A. Human umbilical vein endothelial cells cultivated on microcarriers neutralize factor VIII:C in whole blood. Submitted for publication.
263. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
264. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094-102.
265. 99Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-205.
266. Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83: 2532-40.
267. Shibata S, Sasaki T, Harpel PC, Fillit H. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 1994; 70: 114-23.
268. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
269. Deckert T, Horowitz IM, Kofoed-Enevoldsen A, Kjellen L, Deckert M, Lykkelund C, Burcharth F. Possilbe genetic defects in regulation of glycosaminoglycans in patients with diabetic nephropathy. Diabetes 1991; 40: 764-70.
270. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102: 821-32.
271. Key NS, Platt JL, Vercellotti GM. Vascular endothelial cell proteoglycan are susceptible to cleavage by neutrophils. Arterioscler Thromb 1992; 12: 836-42.
272. Colburn P, Kobayashi E, Buonassisi V. Depleted level of heparan sulfate proteoglycan in the extracellular matrix of endothelial cell cultures exposed to endotoxin. J Cell Physiol 1994; 159: 121-30.
273. Weisdorf DJ, Edson JR. Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II. Br J Haematol 1991; 77: 125-31.
274. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-20.
275. O'Driscoll A, Mackie IJ, Porter JB, Machin SJ. Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion. Br J Haematol 1995; 90: 65-72.
276. Porter JB, Young L, Mackie IJ, Marshall L, Machin SJ. Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol 1993; 83: 459-62.
277. Tollefsen DM, Pestka CA. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 1985; 66: 769-76.
278. Toulon P, Moulonguet-Doleris L, Costa JM, Aiach M. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemost 1991; 65: 20-7.
279. Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW, Andrew M, Delorme M, Ginsberg J, Preissner KT. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995; 73: 405-12.
280. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta-and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990; 144: 383-90.
281. Kaner RJ, Iozzo RV, Ziaie Z, Kefalides NA. Inhibition of proteoglycan synthesis in human endothelial cells after infection with herpes simplex virus type 1 in vitro. Am J Respir Cell Mol Biol 1990; 2: 423-9.
282. 506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
283. Fijnvandraat K, Derbx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73: 15-23.
284. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-45.
285. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
286. Muntean W, Finding K, Gamillscheg A, Zenz W. Multiple thrombosis and coumarin-induced skin necrosis in a young child with antiphospholipid antibodies. Thromb Haemorrh Disorders 1992; 5: 43-51.
287. Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Cardiol 1990; 33: 277-85.
288. Gruber A, Hanson SR, Kelly AB, Van BS, Bang NU, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990; 82: 578-86.
289. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1988; 71: 728-33.
290. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85: 330-8.
291. Uchiba M, Okjima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995; 74: 1265-70.
292. Hasegawa N, Kandra TG, Husari AW, Veiss S, Hart WT, Hedgpeth J, Wydro R, Raffin TA. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am J Resp Crit Care Med 1996; 153: 1831-7.
293. D'Angelo A, Mazzola G, Bergmann F, Safa O, Della-Valle P, D'Angelo SV. Autoimmune protein S deficiency: a disorder predisposing to thrombosis. Haematologica 1995; 80: 114-9.
294. Taylor FB Jr, Dahlbäck B, Chang AC, Lockhart MS, Hatanaka K, Peer G, Esmon CT. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995; 86: 2642-52.
295. Llobet D, Falkon L, Mateo J, Vallve C, Martinez E, Fontcuberta J, Borrell M. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995; 80: 413-22.
296. Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-83.
297. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor. II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989; 74: 994-1002.
298. Sandset PM, Roise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis 1989; 19: 189-98.
299. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematology 1996; 52: 165-70.
300. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-17.
301. Warn-Cramer BJ, Rapaport SI. Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor. Arterioscler Thromb 1993; 13: 1551-9.
302. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor (TFPI) reduces mortality form E. coli septic shock. J Clin Invest 1993; 91: 2850-8.
303. Spokas EG, Wun TC. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods 1992; 27: 225-31.
304. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.